The Pharmaceutical giant, AstraZeneca, has announced the worldwide withdrawal of its Covid-19 vaccine, citing a surplus of updated vaccines tailored for new virus variants. This decision follows the pharmaceutical company’s voluntary withdrawal of its European Union marketing authorization in March, as reported by The Guardian.
On May 7th, the European Medicines Agency officially revoked the authorization for the AstraZeneca vaccine, signaling its discontinuation from use.
“A significant payment in cryptocurrency to be paid in secret within 48 hours to make these issues go away,” Teng stated in a blog post on Binance’s website, highlighting the urgency and clandestine nature of the alleged bribery request.
In their official statement, AstraZeneca explained that the decision stemmed from the availability of newer vaccines specifically designed to combat Covid-19 variants. Consequently, the demand for the AstraZeneca vaccine has dwindled, leading to its cessation in manufacturing and supply.
“Our efforts have been recognized by governments around the world and are widely regarded as being a critical component of ending the global pandemic,” AstraZeneca’s statement noted. “We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic.”
While AstraZeneca’s vaccine played a crucial role in the initial global response, it faced challenges due to rare but serious side effects, such as thrombosis with thrombocytopenia syndrome (TTS). Despite this, the vaccine was acknowledged for its contribution to saving lives during the early stages of the pandemic.
Professor Catherine Bennett from Deakin University acknowledged the pivotal role of the AstraZeneca vaccine in the early stages of the pandemic but noted the shift towards vaccines targeting emerging variants. She emphasized the ongoing evolution in vaccine formulations to align with the latest World Health Organization recommendations targeting specific virus lineages.
